Ponatinib 15 MG

DRUG2 trials

Sponsors

Memorial Sloan Kettering Cancer Center, Fundacion CRIS de Investigación para Vencer el Cáncer

Conditions

Chronic Myeloid Leukemia, Chronic PhaseKRAS Gene MutationNon Small Cell Lung Cancer

Phase 1

Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

CompletedNCT03704688

Memorial Sloan Kettering Cancer CenterKRAS Gene Mutation, Non Small Cell Lung Cancer

Start: 2018-10-09End: 2022-02-04Updated: 2025-05-16

Phase 2

Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP)

Active, not recruitingNCT04160546

Fundacion CRIS de Investigación para Vencer el CáncerChronic Myeloid Leukemia, Chronic Phase

Start: 2020-01-17End: 2025-12-31Target: 80Updated: 2024-12-31

Related Papers

Ponatinib as a consolidation strategy for a second attempt at TKI discontinuation in chronic myeloid leukemia: Interim results from the restop Trial

Blood2025-11-03

P680: PONATINIB 15 MG AS CONSOLIDATION PRIOR TO TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA

HemaSphere2023-08-01